CD33-Targeted Immunotherapeutics in: September 2016 R&D and Business Tracker for TCR & CAR T-Cells and NK Cells

Publisher: La Merie Publishing
Pages: 25
Format: PDF
Product Line:
Monthly Tracking Reports
Product Code: LMBT0004
Release Date: October of 2016

200.00 €
Free of 19 % VAT (except in Germany and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
License:
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

CD33-Targeted Immunotherapeutics in:

September 2016 R&D and Business Tracker for TCR & CAR T-Cells and NK Cells

This pdf report contains information about TCR & CAR engineered T-cells and NK cells released during the month of September 2016. This issue forms part of the subscription service R&D and Business Tracker for TCR & CAR T-Cells and NK Cells

Featured presentations of September 2016 include the pipeline of CD33-targeted immunotherapeutics, the profile of US biotech Eureka Therapeutics and the profile of anti-glypican 3 CAR-T CSG-GPC3 from CARsGen Therapeutics.

The September 2016 issue of our R&D and Business Tracker service about TCR & CAR engineered T-cells and NK cells contains:

R&D and Technology Tracker

  • Pipeline changes
  • Regulatory news
  • Technology validations

Business Tracker for:

  • Company updates
  • Collaboration
  • Licensing
  • Merger & acquisitions
  • Financing

Clinical Trial Tracker
Scientific Publication Tracker
Featured Cell Therapy Profile: CSG-GPC3
Featured Company Profile: Eureka Therapuetics
Featured Target or Technology Pipeline: CD33-Targeted Immunotherapeutics

CD33-Targeted Immunotherapeutics:

  • Antibody-Drug Conjugates
  • Radio-Immunotherapeutics
  • Fc-Engineered Antibodies
  • T-Cell and NK Cell Redirecting Bispecific Antibodies
  • CAR T-Cells

Information about the CD33-Targeted Immunotherapeutics pipeline is provided in a tabular format and fully referenced.

Methodology:
Information released during the previous month is retrieved from a variety of sources including corporate press releases and statements, quarterly company business reports, SEC filings, company presentations, company websites, interviews, webcasts, journal articles, scientific abstracts and reviews, relevant scientific meetings, clinical trial databases, and La Merie Publishing’s proprietary database. Relevant information is presented in textual and tabular formats with disclosure of scientific references or by a hyperlink leading to the source of information.

Customized Update Service:
The above described information service represents our standard module. At an incremental cost, the service can be exclusively widened and customized to specific client needs, e.g. preparation of a preferred presentation format, inclusion of a watch list for tracking, executive summary etc.

Contact us at publishing@lamerie.com to discuss your needs and our ideas of fulfilling them.


The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top